%0 Journal Article
%T The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites
%A Masaaki Shimada
%A Hiroaki Iwase
%A Noboru Hirashima
%A Masashi Saito
%A Hisashi Kondo
%A Noboru Urata
%A Satoshi Unita
%A Takashi Kondo
%A Daiki Tanaka
%J Open Journal of Gastroenterology
%P 39-44
%@ 2163-9469
%D 2018
%I Scientific Research Publishing
%R 10.4236/ojgas.2018.82004
%X We investigated Tolvaptan efficacy and long-term prognosis with focus on nutrition in 20 patients with refractory hepatic ascites in hepatocellular carcinoma (HCC). Bloating improved in 55% of patients, as determined using a Japanese version of the Support Team Assessment Schedule. Nutritional status improved with Tolvaptan treatment, based on the Controlling Nutritional Status score and Onodera¡¯s prognostic nutritional index. Long-term prognosis was better in responders than in non-responders (mean survival time: 308 days vs. 97 days, p = 0.031). Tolvaptan was even effective in many patients with HCC, with additional improvement in long-term prognosis expected with improvement in the nutritional status.
%K Tolvaptan
%K Hepatic Ascites
%K Sarcopenia
%K Loop Diuretics
%K Long-Term Prognosis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=82494